ATAI Life Sciences N.V. — Director's Dealing 2023

Mar 17, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ATAI Life Sciences N.V. (ATAI)
CIK: 0001840904
Period of Report: 2023-03-14

Reporting Person: Bardin Stephen (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-14	Stock Option	$1.18	A	600000	Acquired	2033-03-14	Common Shares (600000)	Direct
2023-03-14	Restricted Stock Unit	$	A	350000	Acquired		Common Shares (350000)	Direct

Footnotes

F1: The stock option shall vest as to 25% of the underlying shares on March 14, 2024, and in 36 substantially equal monthly installments thereafter.

F2: Each restricted stock unit represents a contingent right to receive one common share of the Issuer upon vesting and settlement. 50% of the restricted stock units will vest on the first anniversary of the grant date and 50% will vest on the second anniversary of the grant date.